Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xinyue Capsule in Heart Failure with Preserved Ejection Fraction
NCT06946095Phase 3Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- May 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in heart failure with preserved ejection fraction (HFpEF) comparing Xinyue Capsule + SoC with Standard of Care (2 arms). Primary endpoint: N-terminal pro-brain natriuretic peptide at Week 12. Planned start May 2025; status: not yet recruiting.
02
Drugs
Xinyue Capsule
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06946095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946095.